Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

2021-06-3000016049242021-01-012021-06-300001604924country:DE2021-06-300001604924ifrs-full:OrdinarySharesMember2021-04-012021-04-300001604924ifrs-full:OrdinarySharesMember2021-06-300001604924fwp:ConsultantsMemberfwp:DeferredSharesMember2016-10-102016-10-100001604924ifrs-full:IssuedCapitalMember2021-01-012021-06-300001604924ifrs-full:IssuedCapitalMember2020-01-012020-06-300001604924fwp:IfrsGeneralAndAdministrativeExpenseMember2021-01-012021-06-300001604924fwp:IfrsResearchAndDevelopmentExpenseMember2020-01-012020-06-300001604924fwp:IfrsGeneralAndAdministrativeExpenseMember2020-01-012020-06-300001604924ifrs-full:RetainedEarningsMember2021-06-300001604924ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2021-06-300001604924ifrs-full:IssuedCapitalMember2021-06-300001604924ifrs-full:RetainedEarningsMember2020-12-310001604924ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2020-12-310001604924ifrs-full:IssuedCapitalMember2020-12-310001604924ifrs-full:RetainedEarningsMember2020-06-300001604924ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2020-06-300001604924ifrs-full:IssuedCapitalMember2020-06-300001604924ifrs-full:RetainedEarningsMember2019-12-310001604924ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2019-12-310001604924ifrs-full:IssuedCapitalMember2019-12-310001604924ifrs-full:RetainedEarningsMember2021-01-012021-06-300001604924ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2021-01-012021-06-300001604924ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2020-01-012020-06-3000016049242020-06-3000016049242019-12-310001604924ifrs-full:CountryOfDomicileMember2021-01-012021-06-300001604924country:DEsrt:ScenarioPreviouslyReportedMember2017-01-012017-12-310001604924ifrs-full:CountryOfDomicileMember2017-01-012017-12-310001604924country:DE2017-01-012017-12-310001604924srt:DirectorMember2020-10-102020-10-100001604924country:DE2021-01-012021-06-300001604924fwp:BiogenMemberfwp:ServiceAgreementMember2017-02-0100016049242021-04-300001604924fwp:BiogenMemberfwp:ServiceAgreementMember2017-02-012017-02-280001604924ifrs-full:RetainedEarningsMember2020-01-012020-06-3000016049242016-10-102016-10-1000016049242020-01-012020-06-3000016049242021-06-3000016049242020-12-31iso4217:USDfwp:subsidiaryxbrli:sharesxbrli:pureiso4217:EURiso4217:USDxbrli:sharesfwp:EquityInstruments

Table of Contents

​

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

October 12, 2021

Commission File Number: 001-36686

Forward Pharma A/S

Østergade 24A, 1

1100 Copenhagen K, Denmark

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

​	​
Form 20-F ⌧	Form 40-F ◻

​

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1).

​	​
Yes ◻	No ⌧

​

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7).

​	​
Yes ◻	No ⌧

​

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

​	​
Yes ◻	No ⌧

​

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): N/A

​	​
​	​

​

​

​

1

Table of Contents

EXHIBIT INDEX

	​
Exhibit No.		Description
99.1	​	Unaudited Interim Condensed Consolidated Financial Statements and Notes thereto
	​
99.2	​	Management’s Discussion and Analysis of Financial Condition and Results of Operations
	​

​

​

​

2

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

	Forward Pharma A/S
Date: October 12, 2021	By:	/s/ Claus Bo Svendsen
		Name: Claus Bo Svendsen
		Title: Chief Executive Officer

​

​

3